Cell-based therapies for cardiac repair: A meeting report on scientific observations and European regulatory viewpoints

Martina Schüssler-Lenz, Claire Beuneu, Margarida Menezes-Ferreira, Veronika Jekerle, Jozef Bartunek, Steven Chamuleau, Patrick Celis, Pieter Doevendans, Maura O'Donovan, Jonathan Hill, Marit Hystad, Stefan Jovinge, Ján Kyselovič, Metoda Lipnik-Stangelj, Romaldas Maciulaitis, Krishna Prasad, Anthony Samuel, Olli Tenhunen, Torsten Tonn, Giuseppe RosanoAndreas Zeiher, Paula Salmikangas

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

In the past decade, novel cell-based products have been studied in patients with acute and chronic cardiac disease to assess whether these therapies are efficacious in improving heart function and preventing the development of end-stage heart failure. Cardiac indications studied include acute myocardial infarction (AMI), refractory angina, and chronic heart failure (CHF). Increased clinical activity, experience, and multiple challenges faced by developers have been recognized at the regulatory level. In May 2014, the Committee for Advanced Therapies (CAT) discussed in an expert meeting various cell-based medicinal products developed for cardiac repair, with a focus on non-manipulated bone marrow cells, sorted bone marrow or apheresis, and expanded cells, applied to patients with AMI or CHF. The intention was to share information, both scientific and regulatory, and to examine the challenges and opportunities in this field. These aspects were considered from the quality, and non-clinical and clinical perspectives, including current imaging techniques, with a focus on AMI and CHF. The scope of this overview is to present the European regulatory viewpoint on cell-based therapies for cardiac repair in the context of scientific observations.

Original languageEnglish
Pages (from-to)133-141
Number of pages9
JournalEuropean Journal of Heart Failure
Volume18
Issue number2
DOIs
Publication statusPublished - Feb 1 2016

Fingerprint

Cell- and Tissue-Based Therapy
Heart Failure
Myocardial Infarction
Blood Component Removal
Bone Marrow Cells
Heart Diseases
Chronic Disease
Bone Marrow
Therapeutics

Keywords

  • Advanced therapy medicinal products
  • Cell-based therapies for cardiac repair
  • Committee for Advanced Therapies
  • European regulatory aspects

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Schüssler-Lenz, M., Beuneu, C., Menezes-Ferreira, M., Jekerle, V., Bartunek, J., Chamuleau, S., ... Salmikangas, P. (2016). Cell-based therapies for cardiac repair: A meeting report on scientific observations and European regulatory viewpoints. European Journal of Heart Failure, 18(2), 133-141. https://doi.org/10.1002/ejhf.422

Cell-based therapies for cardiac repair : A meeting report on scientific observations and European regulatory viewpoints. / Schüssler-Lenz, Martina; Beuneu, Claire; Menezes-Ferreira, Margarida; Jekerle, Veronika; Bartunek, Jozef; Chamuleau, Steven; Celis, Patrick; Doevendans, Pieter; O'Donovan, Maura; Hill, Jonathan; Hystad, Marit; Jovinge, Stefan; Kyselovič, Ján; Lipnik-Stangelj, Metoda; Maciulaitis, Romaldas; Prasad, Krishna; Samuel, Anthony; Tenhunen, Olli; Tonn, Torsten; Rosano, Giuseppe; Zeiher, Andreas; Salmikangas, Paula.

In: European Journal of Heart Failure, Vol. 18, No. 2, 01.02.2016, p. 133-141.

Research output: Contribution to journalArticle

Schüssler-Lenz, M, Beuneu, C, Menezes-Ferreira, M, Jekerle, V, Bartunek, J, Chamuleau, S, Celis, P, Doevendans, P, O'Donovan, M, Hill, J, Hystad, M, Jovinge, S, Kyselovič, J, Lipnik-Stangelj, M, Maciulaitis, R, Prasad, K, Samuel, A, Tenhunen, O, Tonn, T, Rosano, G, Zeiher, A & Salmikangas, P 2016, 'Cell-based therapies for cardiac repair: A meeting report on scientific observations and European regulatory viewpoints', European Journal of Heart Failure, vol. 18, no. 2, pp. 133-141. https://doi.org/10.1002/ejhf.422
Schüssler-Lenz, Martina ; Beuneu, Claire ; Menezes-Ferreira, Margarida ; Jekerle, Veronika ; Bartunek, Jozef ; Chamuleau, Steven ; Celis, Patrick ; Doevendans, Pieter ; O'Donovan, Maura ; Hill, Jonathan ; Hystad, Marit ; Jovinge, Stefan ; Kyselovič, Ján ; Lipnik-Stangelj, Metoda ; Maciulaitis, Romaldas ; Prasad, Krishna ; Samuel, Anthony ; Tenhunen, Olli ; Tonn, Torsten ; Rosano, Giuseppe ; Zeiher, Andreas ; Salmikangas, Paula. / Cell-based therapies for cardiac repair : A meeting report on scientific observations and European regulatory viewpoints. In: European Journal of Heart Failure. 2016 ; Vol. 18, No. 2. pp. 133-141.
@article{fc9a5e539aab4079a50f61a392af5fc4,
title = "Cell-based therapies for cardiac repair: A meeting report on scientific observations and European regulatory viewpoints",
abstract = "In the past decade, novel cell-based products have been studied in patients with acute and chronic cardiac disease to assess whether these therapies are efficacious in improving heart function and preventing the development of end-stage heart failure. Cardiac indications studied include acute myocardial infarction (AMI), refractory angina, and chronic heart failure (CHF). Increased clinical activity, experience, and multiple challenges faced by developers have been recognized at the regulatory level. In May 2014, the Committee for Advanced Therapies (CAT) discussed in an expert meeting various cell-based medicinal products developed for cardiac repair, with a focus on non-manipulated bone marrow cells, sorted bone marrow or apheresis, and expanded cells, applied to patients with AMI or CHF. The intention was to share information, both scientific and regulatory, and to examine the challenges and opportunities in this field. These aspects were considered from the quality, and non-clinical and clinical perspectives, including current imaging techniques, with a focus on AMI and CHF. The scope of this overview is to present the European regulatory viewpoint on cell-based therapies for cardiac repair in the context of scientific observations.",
keywords = "Advanced therapy medicinal products, Cell-based therapies for cardiac repair, Committee for Advanced Therapies, European regulatory aspects",
author = "Martina Sch{\"u}ssler-Lenz and Claire Beuneu and Margarida Menezes-Ferreira and Veronika Jekerle and Jozef Bartunek and Steven Chamuleau and Patrick Celis and Pieter Doevendans and Maura O'Donovan and Jonathan Hill and Marit Hystad and Stefan Jovinge and J{\'a}n Kyselovič and Metoda Lipnik-Stangelj and Romaldas Maciulaitis and Krishna Prasad and Anthony Samuel and Olli Tenhunen and Torsten Tonn and Giuseppe Rosano and Andreas Zeiher and Paula Salmikangas",
note = "The article has been reported in 2015",
year = "2016",
month = "2",
day = "1",
doi = "10.1002/ejhf.422",
language = "English",
volume = "18",
pages = "133--141",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "John Wiley & Sons, Ltd",
number = "2",

}

TY - JOUR

T1 - Cell-based therapies for cardiac repair

T2 - A meeting report on scientific observations and European regulatory viewpoints

AU - Schüssler-Lenz, Martina

AU - Beuneu, Claire

AU - Menezes-Ferreira, Margarida

AU - Jekerle, Veronika

AU - Bartunek, Jozef

AU - Chamuleau, Steven

AU - Celis, Patrick

AU - Doevendans, Pieter

AU - O'Donovan, Maura

AU - Hill, Jonathan

AU - Hystad, Marit

AU - Jovinge, Stefan

AU - Kyselovič, Ján

AU - Lipnik-Stangelj, Metoda

AU - Maciulaitis, Romaldas

AU - Prasad, Krishna

AU - Samuel, Anthony

AU - Tenhunen, Olli

AU - Tonn, Torsten

AU - Rosano, Giuseppe

AU - Zeiher, Andreas

AU - Salmikangas, Paula

N1 - The article has been reported in 2015

PY - 2016/2/1

Y1 - 2016/2/1

N2 - In the past decade, novel cell-based products have been studied in patients with acute and chronic cardiac disease to assess whether these therapies are efficacious in improving heart function and preventing the development of end-stage heart failure. Cardiac indications studied include acute myocardial infarction (AMI), refractory angina, and chronic heart failure (CHF). Increased clinical activity, experience, and multiple challenges faced by developers have been recognized at the regulatory level. In May 2014, the Committee for Advanced Therapies (CAT) discussed in an expert meeting various cell-based medicinal products developed for cardiac repair, with a focus on non-manipulated bone marrow cells, sorted bone marrow or apheresis, and expanded cells, applied to patients with AMI or CHF. The intention was to share information, both scientific and regulatory, and to examine the challenges and opportunities in this field. These aspects were considered from the quality, and non-clinical and clinical perspectives, including current imaging techniques, with a focus on AMI and CHF. The scope of this overview is to present the European regulatory viewpoint on cell-based therapies for cardiac repair in the context of scientific observations.

AB - In the past decade, novel cell-based products have been studied in patients with acute and chronic cardiac disease to assess whether these therapies are efficacious in improving heart function and preventing the development of end-stage heart failure. Cardiac indications studied include acute myocardial infarction (AMI), refractory angina, and chronic heart failure (CHF). Increased clinical activity, experience, and multiple challenges faced by developers have been recognized at the regulatory level. In May 2014, the Committee for Advanced Therapies (CAT) discussed in an expert meeting various cell-based medicinal products developed for cardiac repair, with a focus on non-manipulated bone marrow cells, sorted bone marrow or apheresis, and expanded cells, applied to patients with AMI or CHF. The intention was to share information, both scientific and regulatory, and to examine the challenges and opportunities in this field. These aspects were considered from the quality, and non-clinical and clinical perspectives, including current imaging techniques, with a focus on AMI and CHF. The scope of this overview is to present the European regulatory viewpoint on cell-based therapies for cardiac repair in the context of scientific observations.

KW - Advanced therapy medicinal products

KW - Cell-based therapies for cardiac repair

KW - Committee for Advanced Therapies

KW - European regulatory aspects

UR - http://www.scopus.com/inward/record.url?scp=84958110035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958110035&partnerID=8YFLogxK

U2 - 10.1002/ejhf.422

DO - 10.1002/ejhf.422

M3 - Article

AN - SCOPUS:84958110035

VL - 18

SP - 133

EP - 141

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 2

ER -